The Preimplantation Genetic Testing Market research report provides the latest industry data, growth, key segments and future trends on the basis of the detailed study.
This market report also allows you to identify the future opportunity and growth rate of the leading segment based on regions and countries.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the preimplantation genetic testing market include Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., CooperSurgical, Inc., Beijing Genomics Institute, Abbott Laboratories, Natera, Inc., Genea Limited, Rubicon Genomics, Inc., Oxford Gene Technology.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Preimplantation Genetic Testing Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/preimplantation-genetic-testing-market/download-sampleMarket DynamicsThe global foot-operated control panel for the elevator market is projected to grow at a significant pace during the forecast period.
A foot-operated control panel was invented with a concern towards a disabled person.
But soon, the picture is predicted to be changing.
According to a new market research report "Preimplantation Genetic Testing Market by Type (Genetic Diagnosis/Genetic Screening), Technology (NGS, PCR, FISH, CGH, SNP), Products & Services, Application (Aneuploidy, Translocations), End User (Fertility Clinics, Research) - Forecast to 2022", published by MarketsandMarkets™, the Global Preimplantation Genetic Testing Market is projected to reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%.Browse and in-depth TOC on " Preimplantation Genetic Testing Market "85 - Tables42 - Figures204- PagesDownload PDF Brochure:- http://www.marketsandmarkets.com/pdfdownload.asp?id=605By application, the aneuploidy segment is expected to be the fastest growing segment in the forecast period The aneuploidy segment is expected to grow at the fastest CAGR.
Growth of this segment can be attributed to the increasing maternal age, rising incidence of aneuploidy disorders, and strategic initiatives by key players to provide technologically advanced PGS products for aneuploidy screening.Aneuploidy screening has been reported to increase the chance of successful embryo implantation, decreases miscarriage rate, and reduce the chance of having a child with a chromosome abnormality).North America dominated the market in 2016 Geographically, the Preimplantation Genetic Testing Market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.
North America accounted for the largest share of the market in 2016, followed by Europe.
Rising number of IVF procedures (with decreasing fertility rates), significant adoption of genomic techniques, ongoing trend of replacing traditional genomic technologies with advanced and innovative genetic techniques (such as FISH and NGS), and increasing private-public funding to develop and commercialize novel PGS & PGD procedures are the key factors that account for the larger share of the Preimplantation Genetic Testing Market in North America.Talk To Our Research Analysts: -http://www.marketsandmarkets.com/speaktoanalyst.asp?id=605As of 2016, the major product manufacturers operating in the global Preimplantation Genetic Testing Market included Illumina, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Rubicon Genomics, Inc. (U.S.), Oxford Gene Technology (U.K.), Yikon Genomics (China), and SciGene Corporation (U.S.), among others.
Moreover, as of 2016, major service providers active in the global market included Beijing Genomics Institute (BGI) (China), Good Start Genetics (U.S.), CombiMatrix Corporation (U.S.), Genea Limited (Australia), Invicta Genetics (Poland), and Progenesis (U.S.).
The report "Preimplantation Genetic Testing Market by Type (Genetic Diagnosis/Genetic Screening), Technology (NGS, PCR, FISH, CGH, SNP), Products & Services, Application (Aneuploidy, Translocations), End User (Fertility Clinics, Research) - Forecast to 2022", The global preimplantation genetic testing market is projected to reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%.
Early buyers will receive 10% customization on reports.Factors such as the growing rate of infertility across the globe, increasing public-private investments in the field of preimplantation genetic testing, rising number of fertility clinics worldwide, technological advancements in the field of genetic analysis, and high risk of chromosomal abnormalities in the fetus with increasing maternal age are driving the growth of this market.The preimplantation genetic screening segment accounted for the largest share of the market in 2016By type, the preimplantation genetic screening segment accounted for the largest share of the market.
The large share of this segment can primarily be attributed to the decrease in female fertility (due to rising maternal age), increasing prevalence of genetic disorders in offspring, and benefits of PGS, such as increased chances of healthy pregnancy across all age groups, better implantation rate, reduced risks of miscarriage, reduced IVF cycle time, and comprehensive analysis of all 24 chromosome types.By application, the aneuploidy segment is expected to be the fastest growing segment in the forecast periodThe aneuploidy segment is expected to grow at the fastest CAGR.
Aneuploidy screening has been reported to increase the chance of successful embryo implantation, decreases miscarriage rate, and reduce the chance of having a child with a chromosome abnormality).North America dominated the market in 2016Geographically, the preimplantation genetic testing market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.
Rising number of IVF procedures (with decreasing fertility rates), significant adoption of genomic techniques, ongoing trend of replacing traditional genomic technologies with advanced and innovative genetic techniques (such as FISH and NGS), and increasing private-public funding to develop and commercialize novel PGS & PGD procedures are the key factors that account for the larger share of the preimplantation genetic testing market in North America.As of 2016, the major product manufacturers operating in the global market included Illumina, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Rubicon Genomics, Inc. (U.S.), Oxford Gene Technology (U.K.), Yikon Genomics (China), and SciGene Corporation (U.S.), among others.
Moreover, as of 2016, major service providers active in the global market included Beijing Genomics Institute (BGI) (China), Good Start Genetics (U.S.), CombiMatrix Corporation (U.S.), Genea Limited (Australia), Invicta Genetics (Poland), and Progenesis (U.S.).About MarketsandMarkets™MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues.
Factors such as the growing rate of infertility across the globe, increasing public-private investments in the field of preimplantation genetic testing, rising number of fertility clinics worldwide, technological advancements in the field of genetic analysis, and high risk of chromosomal abnormalities in the fetus with increasing maternal age are driving the growth of this market.
The global Preimplantation Genetic Testing Market is projected to reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%.
Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605 By type, the preimplantation genetic screening segment accounted for the largest share of the market.
The large share of this segment can primarily be attributed to the decrease in female fertility (due to rising maternal age), increasing prevalence of genetic disorders in offspring, and benefits of PGS, such as increased chances of healthy pregnancy across all age groups, better implantation rate, reduced risks of miscarriage, reduced IVF cycle time, and comprehensive analysis of all 24 chromosome types.
The aneuploidy segment is expected to grow at the fastest CAGR.
Growth of this segment can be attributed to the increasing maternal age, rising incidence of aneuploidy disorders, and strategic initiatives by key players to provide technologically advanced PGS products for aneuploidy screening.
Factors such as the growing rate of infertility across the globe, increasing public-private investments in the field of preimplantation genetic testing, rising number of fertility clinics worldwide, technological advancements in the field of genetic analysis, and high risk of chromosomal abnormalities in the fetus with increasing maternal age are driving the growth of this market.The report Preimplantation Genetic Testing Market is projected to reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%.Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605Market Segmentation:-By type, the preimplantation genetic screening segment accounted for the largest share of the market.
The large share of this segment can primarily be attributed to the decrease in female fertility (due to rising maternal age), increasing prevalence of genetic disorders in offspring, and benefits of PGS, such as increased chances of healthy pregnancy across all age groups, better implantation rate, reduced risks of miscarriage, reduced IVF cycle time, and comprehensive analysis of all 24 chromosome types.The aneuploidy segment is expected to grow at the fastest CAGR.
Growth of this segment can be attributed to the increasing maternal age, rising incidence of aneuploidy disorders, and strategic initiatives by key players to provide technologically advanced PGS products for aneuploidy screening.Major Market Drivers :- 1 Declining Fertility Rates Worldwide 2 Increasing Public-Private Investments in the Field of Preimplantation Genetic Testing 3 Rising Number of Fertility Clinics Worldwide 4 Technological Advancements in the Field of Genetic Analysis 5 High Risk of Chromosomal Abnormalities With Advancing Maternal AgeRegional Analysis:-Geographically, the Preimplantation Genetic Diagnosis Market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.
North America accounted for the largest share of the market in 2016, followed by Europe.Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=605Top Key players:-As of 2016, the major product manufacturers operating in the global market included Illumina, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Rubicon Genomics, Inc. (U.S.), Oxford Gene Technology (U.K.), Yikon Genomics (China), and SciGene Corporation (U.S.), among others.
Increase in patient awareness about preimplantation genetic manipulation (PGM) technique and rise in prevalence of genetic disorders among infants drive demand for PGM and IVF procedures.
The combination of PGM and IVF has improved the rate of successful pregnancy due to reduced chances of passing the undesired genetic material in the embryo.Read Report Overview - https://www.transparencymarketresearch.com/preimplantation-testing-market.html Usage of array comparative genomic hybridization (aCGH) and fluorescent in situ hybridization (FISH) techniques in PGM has improved the process efficiency and success rate of pregnancy through IVF.
PGM for gender selection and HLA typing is banned in most parts of Asia, whereas it is regulated in the U.S. and in some parts of the European Union.
Regulatory impact plays a major role in analyzing the global preimplantation testing market.Based on type of test, the global preimplantation testing market can be segmented into PGM for chromosomal aberrations, PGM for aneuploidy screening, PGM for gender selection, PGM for single gene disorder, PDG for HLA typing, and PGM for X-linked diseases.
PGM for aneuploidy screening held the largest share in 2016, as aneuploidy could lead to severe abnormalities.
Aneuploidy screening during prenatal testing has a major disadvantage; if the chromosomal abnormality were detected in the fetus, the pregnancy would be terminated.
Index Markets Research cover the present framework on Preimplantation Genetic Diagnosis Market with development prospects and examinations the business potential for each geological district in light of the growth rate, macroeconomic parameters, consumer buying patterns, market demand and supply scenarios.
It provides comprehensive analysis of market trends and dynamics, changing supply and demand scenarios by quantifying market opportunities through market sizing and market forecasting, Tracking current trends, challenges, and Competitive insights.
This Preimplantation Genetic Diagnosis market study presents thorough data which gives the knowledge, scope, and application.
To clarify the market size, the report considers the revenue generated from the various segment.The Preimplantation Genetic Diagnosis market interprets the new industry data and also includes business tactics, development plans, import/export details.
This is a data centric report, primarily consisting of charts and tables.
This report provides trend analysis (market size and forecast) offering a wealth of insights to help companies understand this growing but quickly changing market.
Preimplantation Genetic Testing Market Growth, Trends and Size Analysis by Procedure (Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening), Type (Chromosomal Abnormalities, X-linked Diseases, Embryo Testing, Aneuploidy Screening, LA Typing and others), Application (Embryo HLA Typing for Stem Cell Therapy, IVF Prognosis, Late-Onset Genetic Disorders, Inherited Genetic Disease and others), Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Fluorescence in Situ Hybridization, Comparative Genomic Hybridization, Single-Nucleotide Polymorphism), Product and Service (Reagents and Consumables, Instruments, Software and Services) - Global Forecast till 2027Market HighlightsIt is estimated that the global preimplantation genetic testing market is expected to register a CAGR of 10.2% during the forecast period of 2019 to 2025, with a market value of USD 375.8 million in 2018.Preimplantation genetic testing is the testing at the pre-implantation stage for detection of genetic defects in embryos or oocytes.
Preimplantation genetic testing has occurred more frequently in recent years in North America and Europe, due to the advancement in genetic technology.The decreasing fertility rates worldwide enhance the acceptance of the preimplantation genetic testing to avoid further complications of chromosomal abnormalities with advancing maternal age.
This leads to the growth of the preimplantation genetic testing market during the forecast period.
According to the Vital Statistics Rapid Release, the total fertility rate for the US in 2017 was 1,764.5 births per 1,000 women, and in 2016 it was 1,820.5, which is 3% less, this shows the reduction in the rate of fertility.An increasing number of fertility clinics worldwide, new development technological advancements in the field of genetic analysis and high threat of chromosomal abnormalities with advancing maternal age are the other driving factors for global preimplantation genetic testing marketRequest Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/8121 SegmentationThe global preimplantation genetic testing market is segmented based on procedure, type, application, technology, product and service, end user, and region.The global market for preimplantation genetic testing, by procedure, is segmented into preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS).
The market by end user has been segmented into maternity centers & fertility clinicshospitals, diagnostic labs and research laboratories & academic institutes.
Based on region, the global preimplantation genetic testing market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.Key PlayersSome of the major players in the global preimplantation genetic testing market are Natera, Inc.CooperSurgical, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., IGENOMIX, Reprogenetics, LLC, Genea Limited, PerkinElmer, Inc., Genesis Genetics Ltd., Quest Diagnostics Incorporated, Thermo FisherScientific, Inc, Bioarrayn Genetics, Laboratory Corporation of America Holdings, California Pacific Medical Center and Reproductive Health Science LtdRegional AnalysisThe market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The report "Preimplantation Genetic Testing Market by Type (Genetic Diagnosis/Genetic Screening), Technology (NGS, PCR, FISH, CGH, SNP), Products & Services, Application (Aneuploidy, Translocations), End User (Fertility Clinics, Research) - Forecast to 2022", The global preimplantation genetic testing market is projected to reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%.
Browse 85 Market Data Tables and 42 Figures spread through 204 Pages and in-depth TOC on "Preimplantation Genetic Testing Market by Type (Genetic Diagnosis/Genetic Screening), Technology (NGS, PCR, FISH, CGH, SNP), Products & Services, Application (Aneuploidy, Translocations), End User (Fertility Clinics, Research) - Forecast to 2022" https://www.marketsandmarkets.com/Market-Reports/preimplantation-genetic-testing-market-605.html Early buyers will receive 10% customization on reports.Factors such as the growing rate of infertility across the globe, increasing public-private investments in the field of preimplantation genetic testing, rising number of fertility clinics worldwide, technological advancements in the field of genetic analysis, and high risk of chromosomal abnormalities in the fetus with increasing maternal age are driving the growth of this market.The preimplantation genetic screening segment accounted for the largest share of the market in 2016By type, the preimplantation genetic screening segment accounted for the largest share of the market.
The large share of this segment can primarily be attributed to the decrease in female fertility (due to rising maternal age), increasing prevalence of genetic disorders in offspring, and benefits of PGS, such as increased chances of healthy pregnancy across all age groups, better implantation rate, reduced risks of miscarriage, reduced IVF cycle time, and comprehensive analysis of all 24 chromosome types.By application, the aneuploidy segment is expected to be the fastest growing segment in the forecast periodThe aneuploidy segment is expected to grow at the fastest CAGR.
Aneuploidy screening has been reported to increase the chance of successful embryo implantation, decreases miscarriage rate, and reduce the chance of having a child with a chromosome abnormality).North America dominated the market in 2016Geographically, the preimplantation genetic testing market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.
Rising number of IVF procedures (with decreasing fertility rates), significant adoption of genomic techniques, ongoing trend of replacing traditional genomic technologies with advanced and innovative genetic techniques (such as FISH and NGS), and increasing private-public funding to develop and commercialize novel PGS & PGD procedures are the key factors that account for the larger share of the preimplantation genetic testing market in North America.As of 2016, the major product manufacturers operating in the global market included Illumina, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Rubicon Genomics, Inc. (U.S.), Oxford Gene Technology (U.K.), Yikon Genomics (China), and SciGene Corporation (U.S.), among others.
Moreover, as of 2016, major service providers active in the global market included Beijing Genomics Institute (BGI) (China), Good Start Genetics (U.S.), CombiMatrix Corporation (U.S.), Genea Limited (Australia), Invicta Genetics (Poland), and Progenesis (U.S.).About MarketsandMarkets™MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues.
According to a new market research report "Preimplantation Genetic Testing Market by Type (Genetic Diagnosis/Genetic Screening), Technology (NGS, PCR, FISH, CGH, SNP), Products & Services, Application (Aneuploidy, Translocations), End User (Fertility Clinics, Research) - Forecast to 2022", published by MarketsandMarkets™, the Global Preimplantation Genetic Testing Market is projected to reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%.Browse and in-depth TOC on " Preimplantation Genetic Testing Market "85 - Tables42 - Figures204- PagesDownload PDF Brochure:- http://www.marketsandmarkets.com/pdfdownload.asp?id=605By application, the aneuploidy segment is expected to be the fastest growing segment in the forecast period The aneuploidy segment is expected to grow at the fastest CAGR.
Growth of this segment can be attributed to the increasing maternal age, rising incidence of aneuploidy disorders, and strategic initiatives by key players to provide technologically advanced PGS products for aneuploidy screening.Aneuploidy screening has been reported to increase the chance of successful embryo implantation, decreases miscarriage rate, and reduce the chance of having a child with a chromosome abnormality).North America dominated the market in 2016 Geographically, the Preimplantation Genetic Testing Market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.
North America accounted for the largest share of the market in 2016, followed by Europe.
Rising number of IVF procedures (with decreasing fertility rates), significant adoption of genomic techniques, ongoing trend of replacing traditional genomic technologies with advanced and innovative genetic techniques (such as FISH and NGS), and increasing private-public funding to develop and commercialize novel PGS & PGD procedures are the key factors that account for the larger share of the Preimplantation Genetic Testing Market in North America.Talk To Our Research Analysts: -http://www.marketsandmarkets.com/speaktoanalyst.asp?id=605As of 2016, the major product manufacturers operating in the global Preimplantation Genetic Testing Market included Illumina, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Rubicon Genomics, Inc. (U.S.), Oxford Gene Technology (U.K.), Yikon Genomics (China), and SciGene Corporation (U.S.), among others.
Moreover, as of 2016, major service providers active in the global market included Beijing Genomics Institute (BGI) (China), Good Start Genetics (U.S.), CombiMatrix Corporation (U.S.), Genea Limited (Australia), Invicta Genetics (Poland), and Progenesis (U.S.).
Factors such as the growing rate of infertility across the globe, increasing public-private investments in the field of preimplantation genetic testing, rising number of fertility clinics worldwide, technological advancements in the field of genetic analysis, and high risk of chromosomal abnormalities in the fetus with increasing maternal age are driving the growth of this market.
The global Preimplantation Genetic Testing Market is projected to reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%.
Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605 By type, the preimplantation genetic screening segment accounted for the largest share of the market.
The large share of this segment can primarily be attributed to the decrease in female fertility (due to rising maternal age), increasing prevalence of genetic disorders in offspring, and benefits of PGS, such as increased chances of healthy pregnancy across all age groups, better implantation rate, reduced risks of miscarriage, reduced IVF cycle time, and comprehensive analysis of all 24 chromosome types.
The aneuploidy segment is expected to grow at the fastest CAGR.
Growth of this segment can be attributed to the increasing maternal age, rising incidence of aneuploidy disorders, and strategic initiatives by key players to provide technologically advanced PGS products for aneuploidy screening.
Preimplantation Genetic Testing Market Growth, Trends and Size Analysis by Procedure (Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening), Type (Chromosomal Abnormalities, X-linked Diseases, Embryo Testing, Aneuploidy Screening, LA Typing and others), Application (Embryo HLA Typing for Stem Cell Therapy, IVF Prognosis, Late-Onset Genetic Disorders, Inherited Genetic Disease and others), Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Fluorescence in Situ Hybridization, Comparative Genomic Hybridization, Single-Nucleotide Polymorphism), Product and Service (Reagents and Consumables, Instruments, Software and Services) - Global Forecast till 2027Market HighlightsIt is estimated that the global preimplantation genetic testing market is expected to register a CAGR of 10.2% during the forecast period of 2019 to 2025, with a market value of USD 375.8 million in 2018.Preimplantation genetic testing is the testing at the pre-implantation stage for detection of genetic defects in embryos or oocytes.
Preimplantation genetic testing has occurred more frequently in recent years in North America and Europe, due to the advancement in genetic technology.The decreasing fertility rates worldwide enhance the acceptance of the preimplantation genetic testing to avoid further complications of chromosomal abnormalities with advancing maternal age.
This leads to the growth of the preimplantation genetic testing market during the forecast period.
According to the Vital Statistics Rapid Release, the total fertility rate for the US in 2017 was 1,764.5 births per 1,000 women, and in 2016 it was 1,820.5, which is 3% less, this shows the reduction in the rate of fertility.An increasing number of fertility clinics worldwide, new development technological advancements in the field of genetic analysis and high threat of chromosomal abnormalities with advancing maternal age are the other driving factors for global preimplantation genetic testing marketRequest Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/8121 SegmentationThe global preimplantation genetic testing market is segmented based on procedure, type, application, technology, product and service, end user, and region.The global market for preimplantation genetic testing, by procedure, is segmented into preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS).
The market by end user has been segmented into maternity centers & fertility clinicshospitals, diagnostic labs and research laboratories & academic institutes.
Based on region, the global preimplantation genetic testing market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.Key PlayersSome of the major players in the global preimplantation genetic testing market are Natera, Inc.CooperSurgical, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., IGENOMIX, Reprogenetics, LLC, Genea Limited, PerkinElmer, Inc., Genesis Genetics Ltd., Quest Diagnostics Incorporated, Thermo FisherScientific, Inc, Bioarrayn Genetics, Laboratory Corporation of America Holdings, California Pacific Medical Center and Reproductive Health Science LtdRegional AnalysisThe market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Preimplantation Genetic Testing Market research report provides the latest industry data, growth, key segments and future trends on the basis of the detailed study.
This market report also allows you to identify the future opportunity and growth rate of the leading segment based on regions and countries.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the preimplantation genetic testing market include Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., CooperSurgical, Inc., Beijing Genomics Institute, Abbott Laboratories, Natera, Inc., Genea Limited, Rubicon Genomics, Inc., Oxford Gene Technology.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Preimplantation Genetic Testing Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/preimplantation-genetic-testing-market/download-sampleMarket DynamicsThe global foot-operated control panel for the elevator market is projected to grow at a significant pace during the forecast period.
A foot-operated control panel was invented with a concern towards a disabled person.
But soon, the picture is predicted to be changing.
The report "Preimplantation Genetic Testing Market by Type (Genetic Diagnosis/Genetic Screening), Technology (NGS, PCR, FISH, CGH, SNP), Products & Services, Application (Aneuploidy, Translocations), End User (Fertility Clinics, Research) - Forecast to 2022", The global preimplantation genetic testing market is projected to reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%.
Early buyers will receive 10% customization on reports.Factors such as the growing rate of infertility across the globe, increasing public-private investments in the field of preimplantation genetic testing, rising number of fertility clinics worldwide, technological advancements in the field of genetic analysis, and high risk of chromosomal abnormalities in the fetus with increasing maternal age are driving the growth of this market.The preimplantation genetic screening segment accounted for the largest share of the market in 2016By type, the preimplantation genetic screening segment accounted for the largest share of the market.
The large share of this segment can primarily be attributed to the decrease in female fertility (due to rising maternal age), increasing prevalence of genetic disorders in offspring, and benefits of PGS, such as increased chances of healthy pregnancy across all age groups, better implantation rate, reduced risks of miscarriage, reduced IVF cycle time, and comprehensive analysis of all 24 chromosome types.By application, the aneuploidy segment is expected to be the fastest growing segment in the forecast periodThe aneuploidy segment is expected to grow at the fastest CAGR.
Aneuploidy screening has been reported to increase the chance of successful embryo implantation, decreases miscarriage rate, and reduce the chance of having a child with a chromosome abnormality).North America dominated the market in 2016Geographically, the preimplantation genetic testing market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.
Rising number of IVF procedures (with decreasing fertility rates), significant adoption of genomic techniques, ongoing trend of replacing traditional genomic technologies with advanced and innovative genetic techniques (such as FISH and NGS), and increasing private-public funding to develop and commercialize novel PGS & PGD procedures are the key factors that account for the larger share of the preimplantation genetic testing market in North America.As of 2016, the major product manufacturers operating in the global market included Illumina, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Rubicon Genomics, Inc. (U.S.), Oxford Gene Technology (U.K.), Yikon Genomics (China), and SciGene Corporation (U.S.), among others.
Moreover, as of 2016, major service providers active in the global market included Beijing Genomics Institute (BGI) (China), Good Start Genetics (U.S.), CombiMatrix Corporation (U.S.), Genea Limited (Australia), Invicta Genetics (Poland), and Progenesis (U.S.).About MarketsandMarkets™MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues.
Factors such as the growing rate of infertility across the globe, increasing public-private investments in the field of preimplantation genetic testing, rising number of fertility clinics worldwide, technological advancements in the field of genetic analysis, and high risk of chromosomal abnormalities in the fetus with increasing maternal age are driving the growth of this market.The report Preimplantation Genetic Testing Market is projected to reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%.Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605Market Segmentation:-By type, the preimplantation genetic screening segment accounted for the largest share of the market.
The large share of this segment can primarily be attributed to the decrease in female fertility (due to rising maternal age), increasing prevalence of genetic disorders in offspring, and benefits of PGS, such as increased chances of healthy pregnancy across all age groups, better implantation rate, reduced risks of miscarriage, reduced IVF cycle time, and comprehensive analysis of all 24 chromosome types.The aneuploidy segment is expected to grow at the fastest CAGR.
Growth of this segment can be attributed to the increasing maternal age, rising incidence of aneuploidy disorders, and strategic initiatives by key players to provide technologically advanced PGS products for aneuploidy screening.Major Market Drivers :- 1 Declining Fertility Rates Worldwide 2 Increasing Public-Private Investments in the Field of Preimplantation Genetic Testing 3 Rising Number of Fertility Clinics Worldwide 4 Technological Advancements in the Field of Genetic Analysis 5 High Risk of Chromosomal Abnormalities With Advancing Maternal AgeRegional Analysis:-Geographically, the Preimplantation Genetic Diagnosis Market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.
North America accounted for the largest share of the market in 2016, followed by Europe.Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=605Top Key players:-As of 2016, the major product manufacturers operating in the global market included Illumina, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Rubicon Genomics, Inc. (U.S.), Oxford Gene Technology (U.K.), Yikon Genomics (China), and SciGene Corporation (U.S.), among others.
Increase in patient awareness about preimplantation genetic manipulation (PGM) technique and rise in prevalence of genetic disorders among infants drive demand for PGM and IVF procedures.
The combination of PGM and IVF has improved the rate of successful pregnancy due to reduced chances of passing the undesired genetic material in the embryo.Read Report Overview - https://www.transparencymarketresearch.com/preimplantation-testing-market.html Usage of array comparative genomic hybridization (aCGH) and fluorescent in situ hybridization (FISH) techniques in PGM has improved the process efficiency and success rate of pregnancy through IVF.
PGM for gender selection and HLA typing is banned in most parts of Asia, whereas it is regulated in the U.S. and in some parts of the European Union.
Regulatory impact plays a major role in analyzing the global preimplantation testing market.Based on type of test, the global preimplantation testing market can be segmented into PGM for chromosomal aberrations, PGM for aneuploidy screening, PGM for gender selection, PGM for single gene disorder, PDG for HLA typing, and PGM for X-linked diseases.
PGM for aneuploidy screening held the largest share in 2016, as aneuploidy could lead to severe abnormalities.
Aneuploidy screening during prenatal testing has a major disadvantage; if the chromosomal abnormality were detected in the fetus, the pregnancy would be terminated.
Index Markets Research cover the present framework on Preimplantation Genetic Diagnosis Market with development prospects and examinations the business potential for each geological district in light of the growth rate, macroeconomic parameters, consumer buying patterns, market demand and supply scenarios.
It provides comprehensive analysis of market trends and dynamics, changing supply and demand scenarios by quantifying market opportunities through market sizing and market forecasting, Tracking current trends, challenges, and Competitive insights.
This Preimplantation Genetic Diagnosis market study presents thorough data which gives the knowledge, scope, and application.
To clarify the market size, the report considers the revenue generated from the various segment.The Preimplantation Genetic Diagnosis market interprets the new industry data and also includes business tactics, development plans, import/export details.
This is a data centric report, primarily consisting of charts and tables.
This report provides trend analysis (market size and forecast) offering a wealth of insights to help companies understand this growing but quickly changing market.
The report "Preimplantation Genetic Testing Market by Type (Genetic Diagnosis/Genetic Screening), Technology (NGS, PCR, FISH, CGH, SNP), Products & Services, Application (Aneuploidy, Translocations), End User (Fertility Clinics, Research) - Forecast to 2022", The global preimplantation genetic testing market is projected to reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%.
Browse 85 Market Data Tables and 42 Figures spread through 204 Pages and in-depth TOC on "Preimplantation Genetic Testing Market by Type (Genetic Diagnosis/Genetic Screening), Technology (NGS, PCR, FISH, CGH, SNP), Products & Services, Application (Aneuploidy, Translocations), End User (Fertility Clinics, Research) - Forecast to 2022" https://www.marketsandmarkets.com/Market-Reports/preimplantation-genetic-testing-market-605.html Early buyers will receive 10% customization on reports.Factors such as the growing rate of infertility across the globe, increasing public-private investments in the field of preimplantation genetic testing, rising number of fertility clinics worldwide, technological advancements in the field of genetic analysis, and high risk of chromosomal abnormalities in the fetus with increasing maternal age are driving the growth of this market.The preimplantation genetic screening segment accounted for the largest share of the market in 2016By type, the preimplantation genetic screening segment accounted for the largest share of the market.
The large share of this segment can primarily be attributed to the decrease in female fertility (due to rising maternal age), increasing prevalence of genetic disorders in offspring, and benefits of PGS, such as increased chances of healthy pregnancy across all age groups, better implantation rate, reduced risks of miscarriage, reduced IVF cycle time, and comprehensive analysis of all 24 chromosome types.By application, the aneuploidy segment is expected to be the fastest growing segment in the forecast periodThe aneuploidy segment is expected to grow at the fastest CAGR.
Aneuploidy screening has been reported to increase the chance of successful embryo implantation, decreases miscarriage rate, and reduce the chance of having a child with a chromosome abnormality).North America dominated the market in 2016Geographically, the preimplantation genetic testing market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.
Rising number of IVF procedures (with decreasing fertility rates), significant adoption of genomic techniques, ongoing trend of replacing traditional genomic technologies with advanced and innovative genetic techniques (such as FISH and NGS), and increasing private-public funding to develop and commercialize novel PGS & PGD procedures are the key factors that account for the larger share of the preimplantation genetic testing market in North America.As of 2016, the major product manufacturers operating in the global market included Illumina, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Rubicon Genomics, Inc. (U.S.), Oxford Gene Technology (U.K.), Yikon Genomics (China), and SciGene Corporation (U.S.), among others.
Moreover, as of 2016, major service providers active in the global market included Beijing Genomics Institute (BGI) (China), Good Start Genetics (U.S.), CombiMatrix Corporation (U.S.), Genea Limited (Australia), Invicta Genetics (Poland), and Progenesis (U.S.).About MarketsandMarkets™MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues.